CEBPZ and acute myeloid leukemia: Furthermore, minimal residual disease monitoring has been shown to predict treatment outcome and provide guidance to HSCT indication in CBF-AML.33, 34, 35, 36, 37 Treatment algorithms incorporating mutational profiles and minimal residual disease monitoring should be tested to define whether better risk stratification may be achieved in this AML subtype.